Skip to main content
Premium Trial:

Request an Annual Quote

Agencourt Licenses Kinase Sequencing Assays from Dana-Farber

NEW YORK, May 13 (GenomeWeb News) - Agencourt Bioscience, of Beverly, Mass., has licensed pre-validated SNP sequencing assays for kinases from Dana-Farber Cancer Institute, the company said today.

 

Kinases are implicated in a variety of human diseases, particularly cancer. The sequencing assays, which were developed in the laboratories of Dana-Farber cancer researchers Matthew Meyerson and William Sellers, will be offered as part of Agencourt's SNP discovery service for kinases. The company said that the service will allow analysis of kinase SNPs for "over 92 genes."

 

Financial terms of the agreement were not disclosed.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.